Consun Pharmaceutical Group Limited is a pharmaceutical company that develops, manufactures, and distributes traditional Chinese medicine (TCM) and chemical drugs. The Group operates through key subsidiaries including Guangzhou Consun Medicine Co., Ltd., Guangxi Yulin Pharmaceutical Group Co., Ltd., and Guangzhou Consun Health Technology Co., Ltd. Its product portfolio is organized into therapeutic series covering nephrology, imaging, gynecology and pediatrics, orthopedics, dermatology, hepatobiliary, digestion, and tonifying and calming categories. Notable products include TCM formulations for chronic renal failure and chronic nephritis, as well as chemical drugs such as gadopentetate meglumine for MRI and iopamidol for angiography. The company serves the Chinese market, with a presence in regions including Guangdong, Inner Mongolia, and Guangxi, and maintains a subsidiary in Horgos for cross-border operations. The Group emphasizes product research and development, with a dedicated pharmaceutical research subsidiary and a chief scientist overseeing innovation. It also engages in international investment projects and overseas business development.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Drug Manufacturers - General Homepage chinaconsun.com
Sector Healthcare IR page chinaconsun.com
Tags
traditional chinese medicine, nephrology, imaging contrast agents, gynecology, pediatrics, orthopedics, dermatology, hepatobiliary, digestive health, tonifying and calming, Guangzhou Consun Medicine Co. Ltd., Guangxi Yulin Pharmaceutical Group Co. Ltd., Guangzhou Consun Health Technology Co. Ltd., Guangzhou Consun Pharmaceutical Research Co. Ltd., Consun Pharmaceutical (Inner Mongolia) Co. Ltd., Consun Pharmaceutical (Horgos) Co. Ltd., Guangzhou Consun Pharmaceutical Company Limited, Brilliant Reach Group Limited, Immense Value Holdings Limited, Century International Develop Limited, Grand Reach Company Limited
Press page —

Metrics

Valuation  
Market cap HK$ 13.21B
Market cap (USD) $ 1.684B
P/E 11.06
PEG 0.67
P/BV 2.23
P/S 3.09
P/OCF 7.48
P/FCF —
Dividend yield 5.0%
Turnover / mcap 0.10%
Returns  
ROE 23.4%
ROI 21.4%
ROIC 23.9%
Profit margin 31.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 16.4%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 4.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 41.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Revenue 3.417B 2.967B 2.59B 2.34B 2.045B 1.753B 1.728B 1.844B 1.66B 1.223B 831.108M 730.683M 571.765M 457.801M
Net profit 1.078B 910.458M 784.534M 682.907M 590.172M 498.788M 79.82M 465.353M 396.242M 307.526M 249.689M 211.2M 152.882M 136.206M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Share price 15.63 7.56 — — — 2.91 3.4 5.42 5.63 — — — — —
Price performance 12m 1.12 — — — — -0.14 -0.39 -0.05 — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

FF301

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份:

2026年9月30日

狀態: 新提交

致:香港交易及結算所有限公司 公司名稱:

康臣葯業集團有限公司

呈交日期:

2026年10月5日

I. 法定/註冊股本變動

  1. 股份分類

普通股

股份類別

證券代號 (如上市)

01681

說明

不適用

於香港聯交所上市 (註1)

面值

法定/註冊股份數目 上月底結存

5,000,000,000 HKD

法定/註冊股本 0.1 HKD

500,000,000

HKD

增加 / 減少 (-) 本月底結存

是

5,000,000,000 HKD 本月底法定/註冊股本總額: HKD

第 1 頁共 10 頁

0.1 HKD

500,000,000 500,000,000

v 1.2.1

FF301

II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認

  1. 股份分類

普通股

股份類別

證券代號 (如上市)

01681

說明

不適用

於香港聯交所上市 (註1)

是

庫存股份數目

已發行股份(不包括庫存股份)數目

已發行股份總數

上月底結存

839,049,111

2,498,000

增加 / 減少 (-)

-1,111,317

1,255,000

本月底結存

837,937,794

3,753,000

841,547,111

841,690,794

足夠公眾持股量的確認(註4) 根據《主板上市規則》第13.32D(1)條或第19A.28D(1)條 / 《GEM上市規則》第17.37D(1)條或第25.21D(1)條,我們在此確認,就上述所列股份類別而言,截至本月底: ✔

已符合適用的公眾持股量要求(見下方) 未符合適用的公眾持股量要求(見下方)

根據《主板上市規則》第13.32B條或第19A.28B條 / 《GEM上市規則》第17.37B條或第25.21B條(視情況而定)所載的有關股份類別的最低公眾持股量要求為: 適用的公眾持股量門檻

初始指定門檻 - 上市股份所屬類別的已發行股份總數(不包括庫存股份)的25%

額外信息

第 2 頁共 10 頁

v 1.2.1

FF301

III.已發行股份及/或庫存股份變動詳情 (A). 股份期權(根據發行人的股份期權計劃)

  1. 股份分類

普通股

股份類別

證券代號(如上市)

01681

說明

股份期權計劃詳情

1).

於2013年12月2日採納的購股 權計劃

股東大會通過日期 (如適用) 2).

上月底結存的股份期權數 目

7,074,153 已行使 - 涉及新股

本月內變動

-143,683

是

於香港聯交所上市 (註1)

本月底結存的股份期權數 目

本月內因此發行的新股數 目 (A1)

本月内因此自庫存轉讓的 庫存股份數目 (A2)

本月底因此可能發行或自 庫存轉讓的股份數目

本月底可於所有根據計劃 授出的股份期權予以行使 時發行或自庫存轉讓的股 份總數

6,930,470

143,683

0

6,930,470

0

0

0

0

0

84,281,191

2013年12月2日

於2024年5月31日採納的購股 權計

股東大會通過日期 (如適用)

不適用

0

2024年5月31日

增加已發行股份(不包括庫存股份):

143,683

普通股 (AA1)

減少庫存股份:

0

普通股 (AA2)

本月內因行使期權所得資金總額: HKD

第 3 頁共 10 頁

532,577.63

v 1.2.1

FF301 (B). 承諾發行發行人股份的權證

不適用

第 4 頁共 10 頁

v 1.2.1

FF301 (C). 可換股票據(即可轉換為發行人股份)

不適用

第 5 頁共 10 頁

v 1.2.1

FF301 (D). 為發行發行人股份所訂立的任何其他協議或安排,包括期權(但不包括根據股份期權計劃發行的期權)

第 6 頁共 10 頁

不適用

v 1.2.1

FF301 (E). 已發行股份及/或庫存股份的其他變動

  1. 股份分類

普通股

股份類別

證券代號(如上市)

01681

說明

不適用

價格 (如適用) 事件 貨幣

是

於香港聯交所上市 (註1)

價格

事件發生日期 (註2)

股東大會通過日期 (如適用)

贖回/購回股份(擬註銷但截 本月内因此而增加/減少(-)已 本月内因此而增加/減少(-)庫 至本月底尚未註銷)的數目 發行股份(不包括庫存股 存股份 (E2) (註3) 份)(E1)

1).

購回股份 (股份被持作庫存股份)

HKD

13.1126

2026年9月10日

2026年5月26日

-305,000

305,000

2).

購回股份 (股份被持作庫存股份)

HKD

12.9802

2026年9月11日

2026年5月26日

-406,000

406,000

3).

購回股份 (股份被持作庫存股份)

HKD

13.2437

2026年9月15日

2026年5月26日

-301,000

301,000

4).

購回股份 (股份被持作庫存股份)

HKD

13.0994

2026年9月16日

2026年5月26日

-193,000

193,000

5).

購回股份 (股份被持作庫存股份)

HKD

13.106

2026年9月17日

2026年5月26日

-50,000

50,000

增加/減少(-)已發行股份(不包括庫存股份):

-1,255,000

普通股 (EE1)

增加/減少(-)庫存股份:

1,255,000

普通股 (EE2)

本月内合共增加/減少(-)已發行股份 (不包括庫存股份) 總額 (即AA1至EE1項的總和) :

-1,111,317

普通股

本月内合共增加/減少(-)庫存股份總額 (即AA2至EE2項的總和) :

1,255,000

普通股

第 7 頁共 10 頁

v 1.2.1

FF301

IV. 有關香港預託證券(預託證券)的資料

不適用

第 8 頁共 10 頁

v 1.2.1

FF301

V. 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條,我們在此確認,據我們所知所信,發行人在本月的每項證券發行或庫存股份出售或轉讓(如第III部及第IV部所述但未曾於根據 《主板上市規則》第13.25A條 /《GEM上市規則》第17.27A條所刊發的報表中披露)已獲發行人董事會正式授權批准,並遵照所有適用上市規則、法律及其他監管規定進行,並在適用的情況下: (註5) (i)

上市發行人已收取其在是次證券發行或庫存股份出售或轉讓應得的全部款項;

(ii)

《香港聯合交易所有限公司證券上市規則》「上市資格」項下所規定有關上市的一切先決條件已全部履行;

(iii)

批准證券上市買賣的正式函件內所載的所有條件(如有)已予履行;

(iv)

每類證券在各方面均屬相同(註6);

(v)

《公司(清盤及雜項條文)條例》規定送呈公司註冊處處長存檔的全部文件已經正式存檔,而一切其他法律規定亦已全部遵行;

(vi)

確實所有權文件按照發行、出售或轉讓條款的規定經已發送/現正準備發送/正在準備中並將會發送;

(vii)

發行人的上市文件所示已由其購買或同意購買的全部物業的交易已完成;全部該等物業的購買代價已予繳付;及

(viii)

有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署,有關詳情已送呈公司註冊處處長存檔(如法律如此規定)。

呈交者:

高海恩

職銜:

公司秘書 (董事、秘書或其他獲正式授權的人員)

第 9 頁共 10 頁

v 1.2.1

FF301 註 1.

香港聯交所指香港聯合交易所有限公司。

在購回股份(股份購回並註銷)及贖回股份(股份贖回並註銷)的情況下,「事件發生日期」應理解爲「註銷日期」。 在購回股份(股份被持作庫存股份)的情況下,「事件發生日期」應理解爲「發行人購回並以庫存方式持有股份的日期」。

在購回股份(股份購回擬註銷但尚未註銷)及贖回股份(股份贖回但尚未註銷)的情況下須提供相關資料。請用負數來註明於本月或早前月份購回或贖回但截至本月底尚待註銷的股 份數目。

「初始規定門檻」、「替代門檻」及「市值」的涵義按照《主板上市規則》第13.32A條或第19A.28A條 / 《GEM上市規則》第17.37A條或第25.21A條所界定。有關公眾持股量披露的 依據, 另請參閱《主板上市規則》第13.32D(4)條或19A.28D(4)條 / 《GEM上市規則》第17.37D(4)條或25.21D(4)條。

(i) 至 (viii) 項為確認內容的建議格式。上市發行人可按個別情況就不適用的項目予以修訂。如發行人早前已就某證券發行或庫存股份出售或轉讓於根據《主板上市規則》第13.25A條 / 《GEM上市規則》第17.27A條所刊發的報表中作出有關確認,則不需要於此報表再作確認。

在此「相同」指: ·

證券的面值相同,須繳或繳足的股款亦相同;

·

證券有權領取同一期間內按同一息率計算的股息/利息,下次派息時每單位應獲派發的股息/利息額亦完全相同(總額及淨額);及

·

證券附有相同權益,如不受限制的轉讓、出席會議及於會上投票,並在所有其他方面享有同等權益。

第 10 頁共 10 頁

v 1.2.1

Monthly Returns Bull 1 Bear 0 Routine

FF301

Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities For the month ended:

30 September 2026

Status: New Submission

To : Hong Kong Exchanges and Clearing Limited Name of Issuer:

Consun Pharmaceutical Group Limited

Date Submitted:

05 October 2026

I. Movements in Authorised / Registered Share Capital

  1. Class of shares

Ordinary shares

Type of shares

Stock code (if listed)

01681

Description

Not applicable

Number of authorised/registered shares Balance at close of preceding month

Listed on the Exchange (Note 1)

Par value

5,000,000,000 HKD

Increase / decrease (-) Balance at close of the month

Yes

Authorised/registered share capital 0.1 HKD

500,000,000

HKD 5,000,000,000 HKD Total authorised/registered share capital at the end of the month: HKD

Page 1 of 10

0.1 HKD

500,000,000 500,000,000

v 1.2.1

FF301

II. Movements in Issued Shares and/or Treasury Shares and Public Float Sufficiency Confirmation

  1. Class of shares

Ordinary shares

Type of shares

Stock code (if listed)

01681

Description

Not applicable

Number of issued shares (excluding treasury shares) Balance at close of preceding month Increase / decrease (-) Balance at close of the month

Listed on the Exchange (Note 1)

Number of treasury shares

Yes

Total number of issued shares

839,049,111

2,498,000

-1,111,317

1,255,000

837,937,794

3,753,000

841,547,111

841,690,794

Public float sufficiency confirmation (Note 4) Pursuant to Main Board Rule 13.32D(1) or 19A.28D(1) / GEM Rule 17.37D(1) or 25.21D(1), we hereby confirm that, in relation to the class of shares as set out above, as at the close of the month: ✔ the applicable public float requirement (see below) has been complied with the applicable public float requirement (see below) has not been complied with The applicable minimum public float requirement for the class of shares as set out above pursuant to Main Board Rule 13.32B or 19A.28B / GEM Rule 17.37B or 25.21B (as the case may be) is: Applicable public float threshold

Initial Prescribed Threshold - 25% of the total number of issued shares in the class to which the listed shares belong (excluding treasury shares)

Additional information

Page 2 of 10

v 1.2.1

FF301

III. Details of Movements in Issued Shares and/or Treasury Shares (A). Share Options (under Share Option Schemes of the Issuer)

  1. Class of shares

Ordinary shares

Type of shares

Stock code (if listed)

01681

Description

Particulars of share option scheme

1).

Number of share options outstanding at close of preceding month

Share Option Scheme approved on 02/12/2013

General Meeting approval date (if applicable) 2).

Share Option Scheme approved on 31/05/2024

General Meeting approval date (if applicable)

Not applicable

-143,683

Yes

Number of treasury Number of new shares shares transferred out of issued during the month treasury during the pursuant thereto (A1) month pursuant thereto (A2)

Number of share options outstanding at close of the month

Movement during the month

7,074,153 Exercised - new shares involved

Listed on the Exchange (Note 1)

The total number of Number of shares which shares which may be may be issued or issued or transferred out transferred out of of treasury upon treasury pursuant exercise of all share thereto as at close of options to be granted the month under the scheme at close of the month

6,930,470

143,683

0

6,930,470

0

0

0

0

0

84,281,191

02 December 2013 0

31 May 2024

Increase in issued shares (excluding treasury shares):

143,683

Ordinary shares (AA1)

Decrease in treasury shares:

0

Ordinary shares (AA2)

Total funds raised during the month from exercise of options: HKD

Page 3 of 10

532,577.63

v 1.2.1

FF301 (B). Warrants to Issue Shares of the Issuer

Not applicable

Page 4 of 10

v 1.2.1

FF301 (C). Convertibles (i.e. Convertible into Shares of the Issuer)

Not applicable

Page 5 of 10

v 1.2.1

FF301 (D). Any other Agreements or Arrangements to Issue Shares of the Issuer, including Options (other than Share Option Schemes)

Page 6 of 10

Not applicable

v 1.2.1

FF301 (E). Other Movements in Issued Shares and/or Treasury Shares

  1. Class of shares

Ordinary shares

Type of shares

Stock code (if listed)

01681

Description

Not applicable

At price (if applicable) Events Currency

Date of event (Note 2)

Listed on the Exchange (Note 1)

General Meeting approval date (if applicable)

Increase/ decrease (-) in issued shares (excluding treasury shares) during the month pursuant thereto (E1)

Yes

Increase/ decrease (-) in treasury shares during the month pursuant thereto (E2)

Number of shares redeemed or repurchased for cancellation but not yet cancelled as at close of the month (Note 3)

Amount

1).

Repurchase of shares (shares held as treasury shares)

HKD

13.1126 10 September 2026

26 May 2026

-305,000

305,000

2).

Repurchase of shares (shares held as treasury shares)

HKD

12.9802 11 September 2026

26 May 2026

-406,000

406,000

3).

Repurchase of shares (shares held as treasury shares)

HKD

13.2437 15 September 2026

26 May 2026

-301,000

301,000

4).

Repurchase of shares (shares held as treasury shares)

HKD

13.0994 16 September 2026

26 May 2026

-193,000

193,000

5).

Repurchase of shares (shares held as treasury shares)

HKD

13.106 17 September 2026

26 May 2026

-50,000

50,000

Increase/ decrease (-) in issued shares (excluding treasury shares):

-1,255,000

Ordinary shares (EE1)

Increase/ decrease (-) in treasury shares:

1,255,000

Ordinary shares (EE2)

Total increase/ decrease (-) in issued shares (excluding treasury shares) during the month (i.e. Total of AA1 to EE1):

-1,111,317

Ordinary shares

Total increase/ decrease (-) in treasury shares during the month (i.e. Total of AA2 to EE2):

1,255,000

Ordinary shares

Page 7 of 10

v 1.2.1

FF301

IV. Information about Hong Kong Depositary Receipt (HDR)

Not applicable

Page 8 of 10

v 1.2.1

FF301

V. Confirmations Pursuant to Main Board Rule 13.25C / GEM Rule 17.27C, we hereby confirm to the best knowledge, information and belief that, in relation to each of the securities issued, or the treasury shares sold or transferred by the issuer during the month as set out in Parts III and IV which has not been previously disclosed in a return published under Main Board Rule 13.25A / GEM Rule 17.27A, it has been duly authorised by the board of directors of the listed issuer and carried out in compliance with all applicable listing rules, laws and other regulatory requirements and, insofar as applicable: (Note 5) (i) all money due to the listed issuer in respect of the issue of securities, or sale or transfer of treasury shares has been received by it; (ii) all pre-conditions for listing imposed by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited under "Qualifications of listing" have been fulfilled; (iii) all (if any) conditions contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled; (iv) all the securities of each class are in all respects identical (Note 6); (v) all documents required by the Companies (Winding Up and Miscellaneous Provisions) Ordinance to be filed with the Registrar of Companies have been duly filed and that compliance has been made with all other legal requirements; (vi) all the definitive documents of title have been delivered/are ready to be delivered/are being prepared and will be delivered in accordance with the terms of issue, sale or transfer; (vii) completion has taken place of the purchase by the issuer of all property shown in the listing document to have been purchased or agreed to be purchased by it and the purchase consideration for all such property has been duly satisfied; and (viii) the trust deed/deed poll relating to the debenture, loan stock, notes or bonds has been completed and executed, and particulars thereof, if so required by law, have been filed with the Registrar of Companies.

Submitted by:

Gao Haien

Title:

Company Secretary (Director, Secretary or other Duly Authorised Officer)

Page 9 of 10

v 1.2.1

FF301 Notes 1.

The Exchange refers to The Stock Exchange of Hong Kong Limited.

In the case of repurchase of shares (shares repurchased and cancelled) and redemption of shares (shares redeemed and cancelled), "date of event" should be construed as "cancellation date". In the case of repurchase of shares (shares held as treasury shares), "date of event" should be construed as "date on which shares were repurchased and held by the issuer in treasury".

The information is required in the case of repurchase of shares (shares repurchased for cancellation but not yet cancelled) and redemption of shares (shares redeemed but not yet cancelled). Please state the number of shares repurchased or redeemed during the month or in preceding month(s) but pending cancellation as at close of the month as a negative number.

"Initial Prescribed Threshold”, "Alternative Threshold” and "market value" have the meanings ascribed thereto under Main Board Rule 13.32A or 19A.28A / GEM Rule 17.37A or 25.21A. See also Main Board Rule 13.32D(4) or 19A.28D(4) / GEM Rule 17.37D(4) or 25.21D(4) on the basis of the public float disclosure.

Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases. Where the issuer has already made the relevant confirmations in a return published under Main Board Rule 13.25A / GEM Rule 17.27A in relation to the securities issued, or the treasury shares sold or transferred, no further confirmation is required to be made in this return.

“Identical” means in this context: .

the securities are of the same nominal value with the same amount called up or paid up;

.

they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and

.

they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.

Page 10 of 10

v 1.2.1

通函 - [致登記股東通知信函及回條 ] Bull 0 Bear 0 Routine

(Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) (Stock code / 股份代碼: 1681)

通 知 信 函

各位登記股東:

康臣葯業集團有限公司(「本公司」) – 2026中期報告(「本次公司通訊文件」)之發佈通知

本公司的本次公司通訊文件備有中、英文版本,並已上載於香港聯合交易所有限公司(「香港交易所」)網站(www.hkexnews.hk)及本公司網 站(www.chinaconsun.com),歡迎瀏覽。閣下若因任何理由以致在收取或接收載於本公司網址上的本次公司通訊文件出現困難, 閣下可將要 求(註明 閣下的姓名、地址及要求)以電郵方式發送到本公司之電郵地址[email protected]或以書面方式郵寄致本公司 的香港股份過戶登記分處(「股份過戶分處」)香港中央證券登記有限公司,地址為香港灣仔皇后大道東183號合和中心17M樓。本公司將於接到 閣下 通知後,盡快向 閣下免費發送有關本次公司通訊文件的印刷本。

以電子方式發布公司通訊之安排

根據香港聯合交易所有限公司證券上市規則(「上市規則」)第2.07A條,現謹此通知 閣下,本公司已採用以電子方式發布公司通訊之安 排,該公司通訊是指本公司為向其任何證券持有人提供資訊或提醒其採取行動而發布或將要發布的任何文件,包括但不限於(a) 董事報告、年 度帳目以及審計報告副本以及(如適用)財務摘要報告; (b) 年度報告、中期報告及其報告摘要(如適用); (c) 會議通知; (d) 上市文 件; (e) 通函;及 (f) 委任表格。

請注意,所有日後公司通訊的英文版和中文版將在本公司網站www.chinaconsun.com及香港交易所網站www.hkexnews.hk上提供,以代替印刷 本。

徵集電子聯絡資料

為確保未來及時收到最新的公司通訊,本公司建議 閣下透過掃描本函隨附之回條(「回條」)上列印的 閣下專屬二維碼來提供 閣下的電子郵件地 址。或者, 閣下也可以簽署回條並交回股份過戶分處。

如果股份過戶分處未收到 閣下的有效電子郵件地址,在向股份過戶分處提供有效電子郵件地址之前, 閣下或 (i)無法收到任何有關發布本公司通訊的通 知; (ii)需要主動查看本公司網站和披露易網站以留意公司通訊的發布 ;及 (iii)本公司未來將以印刷本形式發送可供採取行動的公司通訊 (附註) 。

若 閣下希望收取未來的公司通訊及/或可供採取行動的公司通訊之印刷版,請填妥回條並交回股份過戶分處,或發送電子郵件至 [email protected],並註明 閣下的姓名、地址以及收取公司通訊及/或可供採取行動的公司通訊印刷版的要求。 請注意,除非閣下 提前撤回或修改了指示,否則收取未來公司通訊及/或可供採取行動的公司通訊印刷版之指示由收悉 閣下回條當日起計一年內有效,此後將過期。

本公司謹此提醒 閣下,向本公司及/或股份過戶分處提供 閣下正確及有效的聯系方式(包括電子郵箱及聯系地址等)至關重要,任何資料錯誤可能導致 閣下無法及時接收本公司發佈的公司通訊及/或可供採取行動的公司通訊(視實際情況而定)。

如 閣下對本函件有任何疑問,請於辦公時間星期一至五(香港公眾假期除外)上午9時正至下午6時正(香港時間)其間致電股份過戶分處(852)2862 8688 查詢。

承董事局命 康臣葯業集團有限公司 主席 安猛 謹啟

2026年9月24日

附註:公司通訊乃指本公司發出或將予發出以供其任何證券持有人參照或採取行動的任何文件,其中包括但不限於:(a)董事會報告、年度帳目連同核數師報告的副本以及(如適用)財務摘要 報告;(b)中期報告及(如適用)中期摘要報告;(c)會議通告;(d)上市文件;(e)通函;及(f)代表委任表格。根據上市規則第1.01條, 「可供採取行動的公司通訊」指任何涉及要求發行 人的證券持有人指示其擬如何行使其有關 證券持有人的權利或作出選擇的公司通訊。

Please cut the mailing label and stick it on an envelope to return this form to us. No postage is necessary if posted in Hong Kong. 當 閣下寄回此回條時,請將郵寄標籤剪貼於信封上。 如在本港投寄, 閣下無需支付郵費或貼上郵票。

CCS5474 CPAH

REPLY FORM 回條 To: Computershare Hong Kong Investor Services Limited
致: 香港中央證券登記有限公司
(The “Branch Share Registrar”) (「股份過戶分處」) 17M Floor, Hopewell Centre 香港灣仔皇后大道東183號 183 Queen’s Road East, Wanchai, Hong Kong 合和中心17M樓 (Please choose ONLY ONE of the options below)
(請從以下選項中只選擇其中一項) Option 1: Provide your email address for receipt of future Corporate Communications* of
the Company via electronic dissemination by scanning your personalized QR code 選項1: 掃瞄 閣下專屬二維碼提供 閣下之電子郵件地址,以接收公司通過電子方式發布 的未來公司通訊 *

You are NOT required to return this Reply Form if you choose Option 1. 如選擇了選項1, 閣下無須交回本回條。 Personalized QR Code 專屬二維碼

Option 3: I/we hereby request for receipt of Corporate Communications* in printed form (Please mark “✓” in the below box if applicable) 選項3: 本人/吾等現要求收取公司通訊 * 印刷版(如適用,請在以下方格內劃上「✓」號)
receive future Corporate Communications* in printed copy and noted that this instruction shall lapse after one year starting from the receipt date of instruction or until it has been revoked or superseded or you cease to be a registered shareholder of the Company, whichever is earlier. (Notes 5) 收取未來公司通訊 * 的印刷本,並已知悉本指示由收取指示日期起計一年後失效,或直至該指示被撤回或取代或 閣下不再是本公司之登記股東為止,以較早者為準。 (附註5)

Signature(s): (Notes 1)

簽名: (附註1)

Prompts

Consun Pharmaceutical Group Limited (ticker 1681), listed in Hong Kong.

ETFs Holding Consun Pharmaceutical Group Limited

ETF Weight in ETF Shares Market value As of
EYLD 1.00% 4,931,448 $ 8.609M Jul 31, 2026
AVEE 0.11% 71,000 $ 144.215K Nov 16, 2026
REMG 0.06% 43,000 $ 68.972K Jun 30, 2026
AVEM 0.02% 2,025,000 $ 4.113M Nov 16, 2026
AVES 0.02% 113,000 $ 229.526K Nov 16, 2026
AVSE 0.02% 25,000 $ 50.78K Nov 16, 2026
DFEM 0.01% 425,000 $ 855.456K Nov 12, 2026
DFAE 0.00% 152,000 $ 305.951K Nov 12, 2026